Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
  • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
  • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
  • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
  • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
  • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
  • C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
  • C07C205/60—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms in ortho-position to the carboxyl group, e.g. nitro-salicylic acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
  • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
  • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
  • C07C51/377—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C67/00—Preparation of carboxylic acid esters
  • C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C67/00—Preparation of carboxylic acid esters
  • C07C67/10—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond
  • C07C67/11—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond being mineral ester groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/38—Nitrogen atoms
  • C07D277/44—Acylated amino or imino radicals
  • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Definitions

• the present invention relates to a method for selectively demethylating a methoxy group present at the ortho position (position 2) of an aromatic carboxylic acid, and a method for producing an aminothiazole derivative via this method.
• a compound in which 2-hydroxybenzoic acids are amide-bonded to 2-aminothiazoles has an excellent gastrointestinal motility-improving action, upper abdominal complaints, nausea, vomiting, heartburn, anorexia, abdomen It is known to be useful as a prophylactic and therapeutic drug for bloating, reflux esophagitis, etc. (Patent Documents 1 to 3). Of these, the following formula (7a)
• the compound represented by is useful as a prophylactic / therapeutic agent for the above-mentioned various gastrointestinal motility disorders, which have an excellent digestive motility improving action and high safety.
• Patent Document 1 describes that a 2-methylbenzoic acid amide derivative is reacted with a demethylated reagent such as pyridine hydrochloride. The method using 2-hydroxybenzoic acid amide derivatives is adopted. However, in this demethoxylation reaction, many side reactions occur, and it is difficult to selectively demethylate only the 2-position methoxy group, which is a problem for industrial adoption. There was.
• Patent Documents 2 and 3 a 2-methoxybenzoamide amide derivative is reacted with amines such as secondary amine and tertiary amine to selectively remove the methoxy group at the 2-position. It is described that it is methyli. However, the yield of the demethylation reaction of the 2-position methoxy group in this compound was about 64.6 to 86%, which was not yet satisfactory as an industrial method.
• Patent Document 1 W096 / 36619
• Patent Document 2 W098Z58918
• Patent Document 3 Japanese Patent Laid-Open No. 2000-239224
• An object of the present invention is to find a method for selective demethylation of the 2-methoxy group of an aromatic carboxylic acid, and to provide an industrial method for producing an aminothiazole derivative useful as a medicine via this method. There is to do.
• the present inventor conducted various studies on the 2-methoxy group selective demethylation method of aromatic carboxylic acid having a methoxy group at the 2-position, and as a result, a specific Lewis acid, a specific solvent, It was found that only the 2-methoxy group can be selectively demethylated even when a methoxy group is present at the 3, 4, 5 position, etc.
• a means for reacting 2-aminothiazoles with 2-hydroxyaromatic carboxylic acid ester is used for the amidy reaction between 2-hydroxyaromatic carboxylic acids and 2-aminothiazoles. It was found that the process proceeds with extremely high yield.
• ring A represents a benzene ring or a 6-membered aromatic heterocyclic ring
• R 1 represents a hydrogen atom, a lower alkyl group, a halogen atom, a nitro group, an amino group, a mono-lower alkylamino group or a di-
• R 2 , R 3 and R 4 is a lower alkoxy group, a lower alkoxylmethoxy group, a araalkoxy group or an araalkoxylmethoxy group, preferably a methoxy group, and the remainder
• R 5 represents a hydrogen atom or an electron-absorbing I-group
• R 6 represents an alkyl Group
• the present invention reacts a compound of formula (1) with a Lewis acid selected from BF, TiCl and A1C1 in an ester, ketone or amide solvent (however, in the case of BF,
• the present invention also provides a process for producing a compound of formula (3), which comprises reacting a compound of formula (2) with a phenol derivative or a triphenyl phosphite derivative.
• the present invention provides the ability to heat the compound of formula (3) and the compound of formula (4) to 150 ° C or higher.
• the present invention also provides a process for producing a compound represented by formula (7), characterized by reacting a compound represented by formula (5) with N, N-diisopropylethylenediamine in toluene. To do.
• the compound represented by the formula (3) is a novel compound and is extremely important as an intermediate in the method of the present invention.
• the compound represented by the formula (7) useful as a gastrointestinal motility improving agent is obtained in a high yield. And high purity.
• ring A represents a benzene ring or a 6-membered aromatic heterocyclic ring.
• the 6-membered aromatic heterocycle include those containing 1 or 2 selected from a nitrogen atom, an oxygen atom and a sulfur atom.
• the ring include a pyridine ring.
• these aromatic heterocycles have a methoxy group at the ortho position of the carboxyl group, and therefore the ortho position of the carboxyl group or carbonyl group is composed of carbon atoms.
• 3-pyridyl, 4-pyridyl, 5-pyridyl, and 6-pyridyl are preferred.
• Particularly preferred ring A is a benzene ring.
• At least one of R 2 , R 3 and R 4 is a lower alkoxy group, a lower alkoxylmethoxy group, a araalkoxy group or a araalkoxylmethoxy group (preferably a methoxy group).
• R 2 , R 3 and R 4 are a lower alkoxy group, a lower alkoxy methoxy group, a araalkoxy group or a araalkoxyl methoxy group (preferably a methoxy group). Only the methoxy group at the 2-position of the carboxyl group is selectively demethylated.
• Examples of the lower alkoxy group represented by R 2 , R 3 and R 4 include a methoxy group, an ethoxy group and a methylene dioxy group, and examples of the lower alkoxyl methoxy group include a methoxyl methoxy group and an ethoxyl methoxy group.
• Examples of the araalkoxy group include a benzyloxy group, a methoxybenzyloxy group, and a trityloxy group.
• Examples of the araalkoxylmethoxy group include a benzyloxylmethoxy group, a methoxybenzyloxylmethoxy group, and the like.
• an alkyl group having 1 to 6 carbon atoms for example, methylation group, Echiru group, an isopropyl radical, n-butyl group and the like.
• halogen atoms examples thereof include a chlorine atom, a fluorine atom, a bromine atom, and an iodine atom, and among them, a chlorine atom, a fluorine atom, and a bromine atom are preferable.
• Mono-lower alkylamino groups include mono-C
• alkylamino groups such as methylamino group, ethylamino group, isopropylamino group and the like.
• Di-lower alkylamino groups include di-C alkylamino groups such as dimethyl
• Examples include a tyramino group, a jetylamino group, and a diisopropylamino group.
• R 1 is a hydrogen atom, at least one lower alkoxy group R 2 to R 4, the residual lower alkoxy group of R 2 to R 4, lower alkyl
• the group is preferably a group, a halogen atom, a nitrogen group, an amino group, a mono-lower alkylamino group or a di-lower alkylamino group.
• R 1 and R 4 may be a hydrogen atom and R 2 and R 3 may be a lower alkoxy group, a lower alkyl group, a halogen atom, a nitro group, an amino group, a mono-lower alkylamino group, or a di-lower alkylamino group. More preferred.
• R 1 and R 4 are hydrogen atom and R 2 and R 3 is a lower alkoxy group
• R 2 and R 3 particularly R 1 and R 4 are hydrogen atoms U, which is preferably a methoxy group.
• Examples of the electron-withdrawing group represented by R 5 include a halogen (for example, fluorine) atom, a nitro group, a trifluoromethyl group, a trichloromethyl group, a cyano group, a acetyl group, a sulfonic acid group, and an alkylsulfonic acid group. It is done. Of these, -tro group is particularly preferable.
• Examples of the alkyl group represented by R 6 include alkyl groups having 1 to 8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, and 2-ethyl.
• alkyl groups having 1 to 8 carbon atoms such as methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, and 2-ethyl.
• a xyl group etc. are mentioned.
• BF, TiCl and A1C1 may be in the form of a solvate or hydrate, more preferably
• the force of using 1 to 4 times mol, particularly 1.1 to 3 times mol of the compound is preferable from the viewpoint of compatibility of reaction selectivity and reaction efficiency.
• Lewis acids other than these Lewis acids such as Sn-based, Mg-based, Zn-based and Ti (OiPr),
• the alkali metal salt is preferably used in the same mole as the Lewis acid.
• the reaction solvent is an ester, ketone or amide solvent.
• a hydrocarbon solvent such as toluene
• a methoxy group other than the methoxy group at the 2-position is also demethylated, and the compound of the formula (2) cannot be selectively obtained.
• the ester solvent include acetyl acetate, methyl acetate, butyl acetate, isobutyl acetate, and the like.
• the ketone solvent include acetone, 2-butanone, cyclohexanone, and cyclopentanone.
• the amide solvent include dimethylformamide, dimethylacetamide and the like, and among them, dimethylformamide is preferable. In addition to these solvents, other toluene-based solvents may be used.
• the reaction is preferably carried out at 50 to 150 ° C for 0.5 to 5 hours, particularly 60 to 80 ° C for 1 to 3 hours.
• a compound of formula (3) is obtained by reacting a compound of formula (2) with a phenol derivative or a triphenyl phosphite derivative.
• a phenol derivative is used as the phenoling agent, it is preferably carried out in the presence of salt, phosphorus oxychloride or the like.
• a triphenyl phosphite derivative is used as a felting agent, it is preferably carried out in the presence of sulfuric acid, methanesulfonic acid, toluenesulfonic acid, trifluoromethanesulfonic acid or the like.
• phenol derivatives include phenol and para-trophenol.
• the triphenyl phosphite derivatives include triphenyl phosphite and tolypara trifluorophosphate. Triphenyl phosphite is preferred.
• the phenylation reaction is carried out in a hydrocarbon solvent such as toluene, xylene, tetralin, etc. at room temperature to 150 ° C, 1-24 hours, particularly 90-120 ° C, 2-5 hours, f3 ⁇ 4. It's better!
• the compound of formula (5) becomes extremely high. Obtained in yield.
• the solvent for the reaction of the compound of formula (3) and the compound of formula (4) by heating to 150 ° C or higher tetralin, xylene, dimethylformamide, dimethylacetamide, and dimethylsulfoxide are preferable.
• the reaction temperature is less than 150 ° C, the reaction time becomes longer. It is preferably 150 ° C or higher, particularly 150 to 180 ° C. The reaction time is 2 to 5 hours. In this method, although the reaction temperature is high, no side reaction occurs, so that a highly pure compound of the formula (4) can be obtained in a high yield.
• boric acid ester boric acid triphenyl is preferred. In the case of using boric acid triphenyl, side reactions hardly occur, so that a highly pure compound of formula (4) can be obtained in a high yield.
• the reaction solvent is preferably toluene or xylene.
• the reaction is preferably 80 to 120 ° C. The reaction is completed in 1 to 5 hours under these conditions.
• the compound of formula (7) is obtained by reacting the compound of formula (5) with N, N-diisopropylethylenediamine (6) in toluene.
• reaction solution By performing this reaction in toluene, the reaction solution is hardly colored. As a result, the resulting compound of the formula (7) is not colored and the post-treatment becomes simple.
• xylene or tetralin is used as a solvent, the reaction solution tends to be yellowish brown.
• This reaction is 50-150. C, preferably for 1 to 24 hours, particularly 90 to 120 ° C. for 5 to 10 hours.
• the compound of formula (7a) may exist in various acid addition salt forms, but the hydrochloride is preferred. Furthermore, the hydrochloride includes anhydrides, monohydrates, and trihydrates. Among them, trihydrates are particularly excellent in storage stability. When the compound of formula (7a) is recrystallized with an aqueous solution of isopropanol, the trihydrate (7c) can be obtained stably and efficiently.
• the aqueous isopropanol solution used is preferably 10 to 90%.
• the compound of the formula (7c) obtained using an aqueous isopropanol solution is stable to changes in humidity, handling at room temperature, and formulation, and is useful as a raw material for pharmaceuticals.
• the reaction solution was cooled, 4.9 g of 35% hydrochloric acid was added dropwise at 24 ° C, 30 mL of water was added, and the mixture was heated and stirred at 55 ° C for 1 hour.
• the precipitated crystals were collected by filtration and washed with water to obtain 12.45 g of wet crystals of compound (2a).
• Half of the resulting wet crystals (6.23 g) were suspended in 15 mL of water, 3.52 g of 25% (wZw) aqueous sodium hydroxide solution was added dropwise at 18 ° C, and the mixture was heated and stirred at 60 ° C for 1 hour. .
• reaction solution was allowed to cool, 10.4 g of 35% hydrochloric acid was added dropwise, and then 1 mL of water was added, and the mixture was heated and stirred at 70 ° C for 1 hour.
• the precipitated crystals were collected by filtration and washed with water. Drying under reduced pressure at 60 ° C. yielded 1.45 g of compound (2a) in a yield of 73%.
• the selective demethylation of the 2-position methoxy group includes BF -Et 0, T
• (PhO) B is used in place of (MeO) B and xylene (140 ° C) or
• Example 8 The reaction was performed in the same manner as in Example 5 except that xylene or tetralin was used as a reaction solvent. As a result, when toluene was used, the reaction solution was colorless or pale yellow, but xylene or tetralin tended to be colored yellowish brown.
• Example 8
• the obtained crystal (HC1 '3H 2 O) was used in moisture measurement using the Karl Fischer method.
• the measured value is 9.99-10.06% against the theoretical value of 9.98%, suggesting trihydrate.
• the quality remained stable with respect to changes in humidity and handling at room temperature.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• General Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Hospice & Palliative Care (AREA)
• Otolaryngology (AREA)
• Nutrition Science (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Thiazole And Isothizaole Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (21)

Applications Claiming Priority (2)

Related Child Applications (4)

Publications (1)

Family

ID=35967464

Family Applications (1)

Country Status (17)

Cited By (3)

Families Citing this family (19)

Citations (6)

Family Cites Families (4)

• 2005
  • 2005-08-23 KR KR1020077004195A patent/KR101273795B1/ko active IP Right Grant
  • 2005-08-23 HU HUE10010897A patent/HUE027855T2/en unknown
  • 2005-08-23 PT PT100108968T patent/PT2269997E/pt unknown
  • 2005-08-23 PT PT05774659T patent/PT1792888E/pt unknown
  • 2005-08-23 CN CN2010105710460A patent/CN102030654B/zh active Active
  • 2005-08-23 KR KR1020127015092A patent/KR101246449B1/ko active IP Right Grant
  • 2005-08-23 JP JP2006531911A patent/JP4844395B2/ja active Active
  • 2005-08-23 DK DK10010896.8T patent/DK2269997T3/en active
  • 2005-08-23 PT PT100108976T patent/PT2269975E/pt unknown
  • 2005-08-23 WO PCT/JP2005/015259 patent/WO2006022252A1/ja active Application Filing
  • 2005-08-23 EP EP10010620.2A patent/EP2275415B1/en active Active
  • 2005-08-23 PL PL05774659T patent/PL1792888T3/pl unknown
  • 2005-08-23 CN CN2010105710691A patent/CN102040515B/zh active Active
  • 2005-08-23 ES ES10010897.6T patent/ES2544977T3/es active Active
  • 2005-08-23 PL PL10010620T patent/PL2275415T3/pl unknown
  • 2005-08-23 PT PT100106202T patent/PT2275415E/pt unknown
  • 2005-08-23 SI SI200531844T patent/SI2269997T1/sl unknown
  • 2005-08-23 PL PL10010896T patent/PL2269997T3/pl unknown
  • 2005-08-23 KR KR1020127015091A patent/KR101246405B1/ko active IP Right Grant
  • 2005-08-23 EP EP05774659A patent/EP1792888B1/en active Active
  • 2005-08-23 CN CN2005800285378A patent/CN101006040B/zh active Active
  • 2005-08-23 DK DK05774659.6T patent/DK1792888T3/da active
  • 2005-08-23 DK DK10010620.2T patent/DK2275415T3/da active
  • 2005-08-23 PL PL10010897T patent/PL2269975T3/pl unknown
  • 2005-08-23 CA CA2838135A patent/CA2838135C/en active Active
  • 2005-08-23 EP EP10010896.8A patent/EP2269997B1/en active Active
  • 2005-08-23 ES ES10010620.2T patent/ES2438140T3/es active Active
  • 2005-08-23 DK DK10010897.6T patent/DK2269975T3/en active
  • 2005-08-23 AU AU2005275820A patent/AU2005275820B2/en active Active
  • 2005-08-23 EP EP10010897.6A patent/EP2269975B1/en active Active
  • 2005-08-23 ES ES05774659T patent/ES2366037T3/es active Active
  • 2005-08-23 CA CA2576469A patent/CA2576469C/en active Active
  • 2005-08-23 CA CA2838123A patent/CA2838123C/en active Active
  • 2005-08-23 SI SI200531352T patent/SI1792888T1/sl unknown
  • 2005-08-23 CA CA2838137A patent/CA2838137C/en active Active
  • 2005-08-23 ES ES10010896.8T patent/ES2450999T3/es active Active
  • 2005-08-23 AT AT05774659T patent/ATE515490T1/de active
  • 2005-08-23 SI SI200531818T patent/SI2275415T1/sl unknown
  • 2005-08-23 SI SI200532002T patent/SI2269975T1/sl unknown
  • 2005-08-23 KR KR1020127015090A patent/KR101246519B1/ko active IP Right Grant
  • 2005-08-23 CN CN2010105710297A patent/CN102040566B/zh active Active
• 2007
  • 2007-02-02 NO NO20070636A patent/NO338558B1/no unknown
• 2011
  • 2011-08-15 JP JP2011177441A patent/JP5500135B2/ja active Active
  • 2011-09-15 CY CY20111100892T patent/CY1112018T1/el unknown
• 2012
  • 2012-09-12 JP JP2012200199A patent/JP5569569B2/ja active Active
  • 2012-09-12 JP JP2012200202A patent/JP5569570B2/ja active Active
• 2013
  • 2013-10-29 US US14/065,947 patent/US9000163B2/en active Active
  • 2013-10-29 US US14/065,862 patent/US8841461B2/en active Active
  • 2013-10-29 US US14/066,039 patent/US8772528B2/en active Active
• 2014
  • 2014-02-18 CY CY20141100125T patent/CY1114875T1/el unknown
  • 2014-05-22 CY CY20141100360T patent/CY1115103T1/el unknown
• 2015
  • 2015-10-07 CY CY20151100897T patent/CY1116780T1/el unknown
  • 2015-12-17 NO NO20151744A patent/NO338845B1/no unknown
  • 2015-12-17 NO NO20151742A patent/NO338843B1/no unknown
  • 2015-12-17 NO NO20151743A patent/NO338844B1/no unknown

Patent Citations (6)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events